Agoracom Blog
«
»

Weed 2: Cannabis Madness: Dr. Sanjay Gupta Reports

Posted by AGORACOM-JC at 12:21 PM on Thursday, March 13th, 2014
Weed 2: Cannabis Madness: Dr. Sanjay Gupta Reports, premiered Tuesday, March 11th, looks at U.S. federal laws that consider marijuana a drug with no medicinal value and serious scientists who say they’re wrong. It is the politics of pot – the politicians vs. the patients.

Legal in 20 states plus the District of Columbia, limited access to medicinal marijuana has caused significant battles between legislators and qualified patients seeking this type of treatment. Vivian Wilson, a 2-year-old girl suffering from chronic seizures, is one of those patients. Wilson made headlines in 2013 when her father confronted New Jersey Governor Chris Christie pleading “please don’t let my daughter die” and imploring him to legalize medical marijuana in the state.

In the one-hour documentary, Gupta gets exclusive access to the journey of Vivian’s family who, along with many patients, are willing to do anything to get medical marijuana and face many legal challenges along the way. He meets with dozens of families dubbed “medical marijuana refugees” who have moved to Colorado, where pot is legal, to get medical marijuana for their sick children. Gupta also examines disparities in the U.S. government’s research into the benefits of medical marijuana and reports on groundbreaking discoveries in other countries. Gupta’s investigation takes him around the world looking for answers, including a rare inside look at a pharmaceutical company in the United Kingdom that is the only one in the world turning pot into a prescription drug.

Source: Cnn.com

Start your small cap medical marijuana research in the AGORACOM Small Cap Medical Marijuana Stocks Gateway
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Tags: , , ,

This entry was posted on Thursday, March 13th, 2014 at 12:21 pm and is filed under Enertopia, Enertopia Corp., Lexaria Corp., Medical Marijuana Stocks, Next Gen. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Comments are closed.